<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913312</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-AML 2018</org_study_id>
    <nct_id>NCT03913312</nct_id>
  </id_info>
  <brief_title>Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML</brief_title>
  <official_title>Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Navy General Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taian City Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University (Qingdao)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia (AML) is a clonal disease caused by genetic mutations in Hematopoietic
      stem progenitor cells. Unfortunately, advanced age (&gt;60 years old) is considered to be one of
      the most important adverse prognostic factors for AML, and older patients are unable to
      tolerate high-dose chemotherapy, due to various complications and organ dysfunction. Based on
      the results of the previous research, we will carry out the pretreatment regimen of
      decitabine + cytarabine in elderly patients with AML who have achieved disease treatment
      through induction therapy, and continue the transplantation program of unrelated-blood cord
      blood. By assessing the patient's DFS,OS,RFS and safety to determine whether the regimen is
      suitable for the consolidation treatment of elderly acute myeloid leukemia, further clarify
      the efficacy of this regimen compared with traditional consolidation therapy, and initially
      confirm the effect of combined with unrelated cord blood transplantation in the treatment of
      acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective,Multicenter,open,single-arm clinical study.The research process is divided into
      three phases: the screening phase, the treatment phase, and the follow-up phase. The
      treatment phase includes pre-transplant pretreatment, cord blood transplantation, and
      consolidation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Three years</time_frame>
    <description>The time from enrollment to death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate (CR)</measure>
    <time_frame>Three years</time_frame>
    <description>The proportion of cases of hematologic remission that reached the total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (refer to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03).</measure>
    <time_frame>Three years</time_frame>
    <description>Safety/Toxicity Monitoring</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>DAC combined with unrelated cord blood transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC&gt;1.5*107/kg), d0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Unrelated cord blood</intervention_name>
    <description>Unrelated cord blood comes from Shandong cord blood bank. TNC&gt;1.5*107/kg;HLA 4-5/6</description>
    <arm_group_label>DAC combined with unrelated cord blood transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. AML patients diagnosed by bone marrow morphology and Immunology;

          2. Exclusion of APL by Bone marrow morphology or molecular level;

          3. A patient who has obtained bone marrow cytology remission after inductive treatment;

          4. Aged from 60 to 75 years;

          5. Liver and kidney function: blood bilirubin ≤ 35μmol / L, AST or/ALT ＜2 times the upper
             limit of normal (ULN), serum creatinine;≤ 150μmol / L;

          6. The function of Heart is normal;

          7. Physical condition score 0-2 (ECOG score);

          8. Get informed consent signed by patient or family member.

        Exclusion Criteria:

          1. APL patients, treatment-related AML;

          2. Retreatment of patients;

          3. Allergies to any of the drugs involved in the protocol;

          4. There are obvious contraindications to chemotherapy drugs;

          5. Liver and kidney function is obviously abnormal, exceeding the inclusion criteria;

          6. Serious heart disease, including myocardial infarction, cardiac insufficiency;

          7. Suffering from other organ malignant tumors at the same time ;

          8. Active period of tuberculosis patients and HIV-positive patients;

          9. Suffering from other blood system diseases at the same time;

         10. Pregnancy or breastfeeding;

         11. Cannot understand or follow the research plan;

         12. A history of intolerance or allergies to similar drugs;

         13. Patients under 60 years of age or over 75 years of age;

         14. Participate in other clinical researchers at the same time;

         15. There are other situations that hinder the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junmin Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital Affiliated to Shanghai Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junmin Li</last_name>
    <phone>86-21-64374756</phone>
    <email>drlijunmin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junmin Li, M.D.</last_name>
      <email>drlijunmin@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>July 21, 2019</last_update_submitted>
  <last_update_submitted_qc>July 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Li Junmin</investigator_full_name>
    <investigator_title>Director of the hematology department</investigator_title>
  </responsible_party>
  <keyword>AML,Elderly patients,Decitabine,Unrelated cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

